Skip to main content
. 2023 May 3;3(3):327–333. doi: 10.21873/cdp.10219

Table I. Baseline characteristics of patients treated with immune checkpoint inhibitors.

graphic file with name cdp-3-328-i0001.jpg

IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; IQR: Interquartile Range; irAEs: immune-related adverse events; NLR: neutrophil-lymphocyte ratio; RCC: renal cell carcinoma. Statistically significant p-values are shown in bold.